Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2026)

Insight Molecular Diagnostics' FCF Margin history spans 6 years, with the latest figure at 616.68% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 24219.0% to 616.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 625.62%, a 50170.0% increase, with the full-year FY2025 number at 625.62%, up 50170.0% from a year prior.
  • FCF Margin hit 616.68% in Q4 2025 for Insight Molecular Diagnostics, up from 2135.38% in the prior quarter.
  • Over the last five years, FCF Margin for IMDX hit a ceiling of 208.02% in Q4 2021 and a floor of 18291.04% in Q3 2022.
  • Historically, FCF Margin has averaged 2908.93% across 5 years, with a median of 1484.29% in 2023.
  • Biggest five-year swings in FCF Margin: skyrocketed 4226259bps in 2021 and later plummeted -1713485bps in 2022.
  • Tracing IMDX's FCF Margin over 5 years: stood at 208.02% in 2021, then tumbled by -1733bps to 3813.87% in 2022, then surged by 61bps to 1492.99% in 2023, then skyrocketed by 75bps to 374.5% in 2024, then plummeted by -65bps to 616.68% in 2025.
  • Business Quant data shows FCF Margin for IMDX at 616.68% in Q4 2025, 2135.38% in Q3 2025, and 1279.54% in Q2 2025.